An interventional study of Fixed PEEP and BMI-adjusted PEEP in Pulmonary Resection Surgery, One Lung Ventillation (OLV) and General Anesthetic, sponsored by Jesús Manuel Nieves Alonso. Recruiting at 4 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by Jesús Manuel Nieves Alonso · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Hypoxia with a site in Spain — 11 open to participants now, 11 under way, 5 of them phase 3. Hypoxia · Spain.
Among the 31 studies in Hypoxia with a site in Spain, this one is the 4th largest by planned enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2026, is one of 18 with no phase, reaches primary completion later than 9 of the 10 other live ones, and was the 31st registered.
1,081 studies on the registry are indexed under Hypoxia; 213 are open to participants now.
Browse Hypoxia studies →11 of the 31 studies in Hypoxia with a site in Spain are open now. Recruiting first, the newest first:
Iconic Solutions By Murcia SL · Sites in Spain
Ages 18+
Copenhagen Trial Unit, Center for Clinical Intervention Research · Sites in Spain
Ages 0 days–28 days
Universidad Rey Juan Carlos · Sites in Spain
Ages 18–65 · Healthy volunteers
Universidad Rey Juan Carlos · Sites in Spain
Ages 18–65 · Healthy volunteers
Centro Universitario La Salle · Sites in Spain
Ages 18–65 · Healthy volunteers
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 124 Hypoxia studies recruiting now, 52 (42%) set no upper age limit and 46 (37%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 45 across 771 interventional studies indexed under Hypoxia.
Median enrollment 60 across the 25 interventional studies, 150 across the 5 observational. Of the 14 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 31 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Jesús Manuel Nieves Alonso as lead sponsor.
Jesús Manuel Nieves Alonso has 1 study filed under Hypoxia — fewer than ten, so there is no comparison to draw.
1 of the studies in Hypoxia with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07432191Iconic Solutions By Murcia SLMedical Device Clinical Trial Without CE Marking to Evidence Safety and Performance of the INBENTUS VERSATILE Ventilator in Patients Requiring Assisted/Controlled Mechanical Ventilation and Weaning. | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 31 studies in Hypoxia with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
One-lung ventilation (OLV) is required during many thoracic surgical procedures and is associated with reduced functional residual capacity, atelectasis, ventilation-perfusion mismatch, hypoxemia, and potentially ventilator-induced lung injury. Lung-protective ventilation strategies include low tidal volumes, limitation of airway pressures, and positive end-expiratory pressure (PEEP), but the optimal PEEP level during OLV remains uncertain. Fixed PEEP is simple and reproducible but does not account for individual patient characteristics. Body mass index (BMI) is readily available before anesthesia and is associated with respiratory mechanics, making it a pragmatic candidate for simple PEEP individualization.
SIMPLE-PEEP is a prospective, multicenter, pragmatic, open-label, randomized clinical trial including 150 adults undergoing elective pulmonary resection under general anesthesia requiring OLV. Participants will be randomized to either fixed PEEP of 4 cmH2O or BMI-adjusted PEEP calculated as BMI/3 cmH2O. Other key components of lung-protective ventilation will be standardized between groups.
The primary outcome is driving pressure during the first 20 minutes of OLV, assessed at 5, 10, and 20 minutes after OLV initiation. Secondary outcomes include respiratory system compliance and other respiratory mechanics, estimated mechanical power, oxygenation, intraoperative hypoxemia and rescue maneuvers, hemodynamic safety, vasopressor requirements, and exploratory postoperative respiratory outcomes. No investigational medicinal product, additional invasive procedure, or study-specific advanced monitoring is required.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Procedure: Fixed PEEP
Procedure: BMI-adjusted PEEP
Fixed PEEP of 4 cmH2O
BMI-adjusted PEEP calculated as BMI/3 cmH2O
Driving pressure during the primary T2-T4 window
Driving pressure during the primary T2-T4 window, measured at 5, 10, and 20 minutes after initiation of one-lung ventilation and expressed in cmH2O. In conventional volume-controlled ventilation, driving pressure is calculated as plateau pressure minus applied PEEP. In pressure-regulated volume-targeted/volume-guaranteed modes, driving pressure is calculated as total end-inspiratory pressure minus applied PEEP.
Time frame: 20 minutes
Respiratory system compliance
Respiratory system compliance will be calculated at each applicable time point as tidal volume divided by driving pressure and expressed in mL/cmH2O
Time frame: At 5, 10, and 20 minutes after initiation of one-lung ventilation; at 60 minutes when applicable; and at the end of one-lung ventilation, all during the surgical procedure on Day 1.
Driving pressure at 60 minutes and at the end of one-lung ventilation
Driving pressure will be assessed at 60 minutes after initiation of one-lung ventilation, when this time point is applicable, and at the actual end of one-lung ventilation, to evaluate the persistence of the physiological effect of the assigned PEEP strategy.
Time frame: At 60 minutes after initiation of one-lung ventilation, when applicable, and at the end of one-lung ventilation.
Estimated mechanical power during one-lung ventilation
Ventilatory mechanical power will be estimated from prospectively recorded ventilatory parameters using a prespecified calculation method appropriate to the ventilation mode and expressed in J/min.
Time frame: At 5, 10, and 20 minutes after initiation of one-lung ventilation; at 60 minutes when applicable; and at the end of one-lung ventilation, all during the surgical procedure on Day 1.
Incidence of intraoperative hypoxemia during one-lung ventilation
Intraoperative hypoxemia will be defined as SpO2 \<90% sustained for at least 60 seconds during one-lung ventilation with baseline FiO2 0.6, or any episode of SpO2 \<90% requiring immediate clinical intervention at the discretion of the attending anesthesiologist.
Time frame: From initiation until completion of one-lung ventilation during the surgical procedure on Day 1 (up to 1 day).
Incidence of major ventilatory rescue
Major ventilatory rescue during the first 20 minutes after initiation of one-lung ventilation will be defined as any intervention that substantially modifies the assigned ventilatory strategy or respiratory mechanics, including modification of PEEP from the assigned value, recruitment maneuver, CPAP to the non-ventilated lung, temporary restoration of two-lung ventilation, or protocol interruption for safety reasons.
Time frame: During the first 20 minutes after initiation of one-lung ventilation on Day 1.
Incidence of intraoperative hypotension
Intraoperative hypotension will be defined as mean arterial pressure \<65 mmHg sustained for more than 1 minute.
Time frame: Intraoperative/periprocedural period on Day 1, from induction of anesthesia until the end of surgery.
Requirement for intraoperative vasopressor support
Proportion of participants requiring vasopressor administration during the intraoperative period. Vasopressor use will be recorded as a measure of the hemodynamic safety of the assigned PEEP strategy.
Time frame: Time Frame: Intraoperative/periprocedural period on Day 1, from induction of anesthesia until the end of surgery.
Incidence of postoperative pulmonary complications
Occurrence of at least one prespecified postoperative pulmonary complication, including acute respiratory failure, pneumonia, acute respiratory distress syndrome, atelectasis, pneumothorax, bronchopleural fistula, aspiration pneumonitis, pulmonary embolism, pleural empyema, bronchospasm, pleural effusion, or need for postoperative respiratory support or reintubation for respiratory deterioration. This outcome will be considered exploratory.
Time frame: From the end of surgery until hospital discharge during the index hospitalization (estimated average duration: 3-10 days).
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Started Oct 2026 (actual). Primary completion is estimated for Mar 2028, 16 months after the start.
Of 324 non-industry interventional studies with no phase under Hypoxia, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 27. This study's planned 16 months is above that.
Counting every sponsor, half of 354 studies reached it within 12 months; a quarter within 3 and three quarters within 27.
Start moved once since we started tracking on Sep 25, 2026: Nov 2026 → Oct 2026, on Oct 9, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.